NCT04129515View on ClinicalTrials.gov

NovoTTF-200A + Pembrolizumab In Melanoma Brain Metastasis

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 30, 2025

Primary Completion Date

March 31, 2026

Study Completion Date

January 31, 2027

Conditions
Metastatic MelanomaMelanoma Brain Metastasis
Interventions
DEVICE

NovoTTF-200A

•NovoTTF-200A will be applied continuously, with 21 consecutive days defined as a treatment cycle

DRUG

Pembrolizumab

Pembrolizumab will be administered once every 3 weeks, with 21 consecutive days also defined as a treatment cycle

Trial Locations (1)

02903

Lifespan Cancer Institute, Providence

Sponsors

Lead Sponsor

Brown University
All Listed Sponsors
collaborator

NovoCure Ltd.

INDUSTRY

lead

Brown University

OTHER

NCT04129515 - NovoTTF-200A + Pembrolizumab In Melanoma Brain Metastasis | Biotech Hunter | Biotech Hunter